| 1 |
31134657 | Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1. | 2019 Nov |
1 |
| 2 |
22149256 | Clinical pharmacokinetics of fingolimod. | 2012 Jan 1 |
1 |
| 3 |
21045201 | CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. | 2011 Feb |
2 |
| 4 |
19118083 | Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. | 2009 Feb |
3 |
| 5 |
16997912 | CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. | 2006 Dec |
1 |
| 6 |
14709627 | Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. | 2004 Jan |
1 |